Yu Jing, Liu Ting-Ting, Liang Lei-Lei, Liu Jing, Cai Hong-Qing, Zeng Jia, Wang Tian-Tian, Li Jian, Xiu Lin, Li Ning, Wu Ling-Ying
Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Department of Blood Grouping, Beijing Red Cross Blood Center, Beijing, 100088, China.
Cancer Cell Int. 2021 Jul 6;21(1):353. doi: 10.1186/s12935-021-02045-0.
Ovarian cancer (OC) is the most lethal gynaecological tumor. Changes in glycolysis have been proven to play an important role in OC progression. We aimed to identify a novel glycolysis-related gene signature to better predict the prognosis of patients with OC.
mRNA and clinical data were obtained from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Genotype Tissue Expression (GTEx) database. The "limma" R package was used to identify glycolysis-related differentially expressed genes (DEGs). Then, a multivariate Cox proportional regression model and survival analysis were used to develop a glycolysis-related gene signature. Furthermore, the TCGA training set was divided into two internal test sets for validation, while the ICGC dataset was used as an external test set. A nomogram was constructed in the training set, and the relative proportions of 22 types of tumor-infiltrating immune cells were evaluated using the "CIBERSORT" R package. The enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were determined by single-sample gene set enrichment analysis (ssGSEA) with the "GSVA" R package. Finally, the expression and function of the unreported signature genes ISG20 and SEH1L were explored using immunohistochemistry, western blotting, qRT-PCR, proliferation, migration, invasion and xenograft tumor assays.
A five-gene signature comprising ANGPTL4, PYGB, ISG20, SEH1L and IRS2 was constructed. This signature could predict prognosis independent of clinical factors. A nomogram incorporating the signature and three clinical features was constructed, and the calibration plot suggested that the nomogram could accurately predict the survival rate. According to ssGSEA, the signature was associated with KEGG pathways related to axon guidance, mTOR signalling, tight junctions, etc. The proportions of tumor-infiltrating immune cells differed significantly between the high-risk group and the low-risk group. The expression levels of ISG20 and SEH1L were lower in tumor tissues than in normal tissues. Overexpression of ISG20 or SEH1L suppressed the proliferation, migration and invasion of Caov3 cells in vitro and the growth of xenograft tumors in vivo.
Five glycolysis-related genes were identified and incorporated into a novel risk signature that can effectively assess the prognosis and guide the treatment of OC patients.
卵巢癌(OC)是最致命的妇科肿瘤。糖酵解变化已被证明在OC进展中起重要作用。我们旨在鉴定一种新的糖酵解相关基因特征,以更好地预测OC患者的预后。
从癌症基因组图谱(TCGA)、国际癌症基因组联盟(ICGC)和基因型组织表达(GTEx)数据库中获取mRNA和临床数据。使用“limma”R包鉴定糖酵解相关差异表达基因(DEG)。然后,使用多变量Cox比例回归模型和生存分析来开发糖酵解相关基因特征。此外,将TCGA训练集分为两个内部测试集进行验证,而ICGC数据集用作外部测试集。在训练集中构建列线图,并使用“CIBERSORT”R包评估22种肿瘤浸润免疫细胞的相对比例。通过使用“GSVA”R包的单样本基因集富集分析(ssGSEA)确定富集的京都基因与基因组百科全书(KEGG)通路。最后,使用免疫组织化学、蛋白质印迹、qRT-PCR、增殖、迁移、侵袭和异种移植肿瘤试验探索未报道的特征基因ISG20和SEH1L的表达和功能。
构建了一个由ANGPTL4、PYGB、ISG20、SEH1L和IRS2组成的五基因特征。该特征可以独立于临床因素预测预后。构建了一个包含该特征和三个临床特征的列线图,校准图表明该列线图可以准确预测生存率。根据ssGSEA,该特征与轴突导向、mTOR信号传导、紧密连接等相关的KEGG通路有关。高风险组和低风险组之间肿瘤浸润免疫细胞的比例存在显著差异。肿瘤组织中ISG20和SEH1L的表达水平低于正常组织。ISG20或SEH1L的过表达在体外抑制Caov3细胞的增殖、迁移和侵袭,在体内抑制异种移植肿瘤的生长。
鉴定出五个糖酵解相关基因并将其纳入一个新的风险特征中,该特征可以有效评估OC患者的预后并指导治疗。